Your trusted source for investing success

Tag: Twitter

DelMar Pharmaceuticals Receives Approval from China’s Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM

DelMar Pharmaceuticals Receives Approval from China’s Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the Human Genetic Resources Administration of China (HGRAC), has approved the Company’s application to initiate a Phase 2 safety and efficacy study of its lead product candidate VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma

National Research Council and Lexaria Bioscience Commence Laboratory Work

National Research Council and Lexaria Bioscience Commence Laboratory Work

Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) announces the start of laboratory work under its collaborative research program with the National Research Council of Canada (“NRC”), following the completion of preparation initiatives announced on March 14, 2017.

As earlier reported, several studies will be initiated in the coming months designed to optimize Lexaria’s patented technology

Isodiol International Inc. signs definitive licensing agreement with Canopy Growth Corporation for Canadian and international distribution

Isodiol International Inc. signs definitive licensing agreement with Canopy Growth Corporation for Canadian and international distribution

Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (Frankfurt: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has signed a licensing agreement with Canopy Growth Corporation (“Canopy”) (TSX:WEED).  

Canopy Growth is the world’s premier cannabis company that

Lexaria Bioscience Awarded Australian Patent For Cannabinoid Infused Edibles

Lexaria Bioscience Awarded Australian Patent For Cannabinoid Infused Edibles

Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) is pleased to announce that the Australian Patent Office has granted patent #2015274698 which protects Lexaria’s method of improving absorption, speed of onset, and taste of cannabinoid active agents in edible products. The term of the patent is 20 years from June 10, 2015.

The issuance of this

DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the completion of the first site initiation visit at the Dent Neurological Institute (“Dent”) for its pivotal Phase 3 Study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (“STAR-3”).  Site initiation visits are generally the final step before patient enrollment.

The

Taku acquires Keynote Gold Project in Keno Hill area of Yukon

Taku Gold Corp. (CSE:TAK)(CSE:TAK.CN)(CNSX:TAK) (“Taku” or the “Company”) is pleased to announce that it has agreed to purchase a 100% interest in the 77-claim (1,518-hectare) Keynote property (“Keynote” or the “Property”) located in the Mayo Mining District of Yukon. The Property was acquired by an agreement executed with two arm’s

Azarga Uranium Announces $1.5 Million Private Placement

Azarga Uranium Announces $1.5 Million Private Placement

AZARGA URANIUM CORP. (TSX:AZZ)(FRANKFURT:P8AA)(OTC PINK:PWURF)(“Azarga Uranium” or the “Company”) announces that it intends to issue 5,800,000 units (each, a “Unit”) at a price of $0.26 per Unit to raise proceeds of $1.5 million through a non-brokered private placement (“the Financing”).

The Company intends to use the proceeds of the Financing to

Isodiol International Inc. Announces Corporate Update

Isodiol International Inc. Announces Corporate Update

Isodiol International Inc. (CSE:ISOL) (OTC: LAGBF) (FSE: LB6A.F) a global cannabis innovator specializing in the development of pharmaceutical and consumer products, today released its unaudited consolidated sales figures for the month of June 2017. The company recorded sales of $1,843,173 CAD for the thirty-day period ended June 30, 2017.  Total

Azarga Uranium Corp: Annual General and Special Meeting 2017 Voting Results

Azarga Uranium Corp: Annual General and Special Meeting 2017 Voting Results

AZARGA URANIUM CORP. (TSX:AZZ)(FRANKFURT:P8AA)(OTC PINK:PWURF)(“Azarga Uranium” or the “Company”) announces that all resolutions put forward at the Annual General and Special Meeting (the “Meeting”) of the Company’s shareholders (the “Shareholders”), as further described in the Company’s information circular dated 25 May 2017, were approved, including the following:

Setting the number

Enter Your Log In Credentials
×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network